1. In Vivo
  2. >>Global Vision

PowderMed's Vaccines: Out of Chiron, Into the Clinic

 
• By Chris Morrison

The spinout of PowderJect's DNA vaccine technology following that company's acquisition by Chiron in mid-2003 was no surprise-these powder-injection assets are far too early-stage in the context of Chiron's vaccines pipeline. But newly minted PowderMed is no ordinary start-up. Despite the high-risk nature of its technology, the firm begins life with £20 million from four blue chip VCs, Big Pharma endorsement provided by GSK, five projects expected to enter the clinic within two years, and management that has overseen development of these products for more than six years.

The spinout of PowderJect's DNA vaccine technology following that company's acquisition by Chiron in mid-2003 was no surprise—these powder-injection assets are far too early-stage in the context of Chiron's vaccines pipeline. But newly minted PowderMed is no ordinary start-up. Despite the high-risk nature of its technology, the firm begins life with £20 million from four blue chip VCs, Big Pharma endorsement provided by GSK, five projects expected to enter the clinic within two years, and management that has overseen development of these products for more than six years.

The £542 million ($959 million) that Chiron spent acquiring Powderject Pharmaceuticals in mid-2003 was a move by the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By Jo Shorthouse

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Execs On The Move: May 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.